CA2874057A1 - New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof - Google Patents

New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof Download PDF

Info

Publication number
CA2874057A1
CA2874057A1 CA2874057A CA2874057A CA2874057A1 CA 2874057 A1 CA2874057 A1 CA 2874057A1 CA 2874057 A CA2874057 A CA 2874057A CA 2874057 A CA2874057 A CA 2874057A CA 2874057 A1 CA2874057 A1 CA 2874057A1
Authority
CA
Canada
Prior art keywords
alk
compound
cancer
alkoxy
haloalkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874057A
Other languages
English (en)
French (fr)
Inventor
Melissa L. Fishel
Patrick Thomas Gunning
Sina HAFTCHENARY
Samuel Weiss
Hema Artee Luchman
Brent David George Page
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UTI LP
University of Toronto
Indiana University Bloomington
Original Assignee
UTI LP
University of Toronto
Indiana University Bloomington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTI LP, University of Toronto, Indiana University Bloomington filed Critical UTI LP
Publication of CA2874057A1 publication Critical patent/CA2874057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
CA2874057A 2012-05-25 2013-05-24 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof Abandoned CA2874057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651757P 2012-05-25 2012-05-25
US61/651,757 2012-05-25
PCT/US2013/042689 WO2013177534A2 (en) 2012-05-25 2013-05-24 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Publications (1)

Publication Number Publication Date
CA2874057A1 true CA2874057A1 (en) 2013-11-28

Family

ID=49624538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874057A Abandoned CA2874057A1 (en) 2012-05-25 2013-05-24 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Country Status (9)

Country Link
US (3) US9650399B2 (enExample)
EP (1) EP2854819B1 (enExample)
JP (2) JP6290871B2 (enExample)
CN (2) CN110003104A (enExample)
BR (1) BR112014029439A2 (enExample)
CA (1) CA2874057A1 (enExample)
HK (1) HK1218709A1 (enExample)
RU (1) RU2641903C2 (enExample)
WO (1) WO2013177534A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179956A1 (en) * 2014-05-30 2015-12-03 The Governing Council Of The University Of Toronto Sulfonamide compounds and their use as stat5 inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6570512B2 (ja) * 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤
EP3570836A4 (en) * 2017-01-23 2020-08-19 The University of Hawaii 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE STAT3 INHIBITORS
CN113661158A (zh) * 2018-12-21 2021-11-16 多伦多大学管理委员会 新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN115551496A (zh) * 2020-03-05 2022-12-30 詹皮克斯有限公司 Stat抑制性化合物和组合物
JP2023515236A (ja) * 2020-03-05 2023-04-12 ジャンピックス，エルティーディ． α置換されたＳＴＡＴ阻害剤およびその組成物
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN112941036B (zh) * 2021-02-08 2023-06-09 吉林惠康生物药业有限公司 一种提高狂犬病毒在人二倍体细胞中复制水平的方法
CN114751927B (zh) * 2022-03-08 2023-10-31 中山大学 一种硼酸化合物、制备方法及用途
CN118994047B (zh) * 2024-08-13 2026-02-10 中国药科大学 一种水杨醛衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487156B1 (en) * 2003-12-11 2014-07-16 Board Of Regents The University Of Texas System Compounds for treatment of cell proliferative diseases
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
NZ590355A (en) * 2008-07-10 2013-01-25 Yakult Honsha Kk Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
CA2757912A1 (en) 2009-04-06 2010-10-14 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
US8846707B2 (en) 2010-08-02 2014-09-30 Univeristy Of Central Florida Research Foundation, Inc. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein
JP6570512B2 (ja) * 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179956A1 (en) * 2014-05-30 2015-12-03 The Governing Council Of The University Of Toronto Sulfonamide compounds and their use as stat5 inhibitors
CN106458873A (zh) * 2014-05-30 2017-02-22 多伦多大学管理委员会 磺酰胺化合物和它们作为stat5抑制剂的用途
US10519107B2 (en) 2014-05-30 2019-12-31 The Governing Council Of The University Of Toronto Sulfonamide compounds and their use as STAT5 inhibitors
CN112979510A (zh) * 2014-05-30 2021-06-18 多伦多大学管理委员会 磺酰胺化合物和它们作为stat5抑制剂的用途

Also Published As

Publication number Publication date
JP6290871B2 (ja) 2018-03-07
EP2854819B1 (en) 2020-01-15
CN105120854B (zh) 2019-04-09
BR112014029439A2 (pt) 2017-06-27
EP2854819A4 (en) 2016-06-15
RU2014152697A (ru) 2016-07-20
US20190382422A1 (en) 2019-12-19
HK1218709A1 (zh) 2017-03-10
CN110003104A (zh) 2019-07-12
US20150158894A1 (en) 2015-06-11
JP2018109017A (ja) 2018-07-12
CN105120854A (zh) 2015-12-02
RU2641903C2 (ru) 2018-01-23
WO2013177534A2 (en) 2013-11-28
US20170267704A1 (en) 2017-09-21
WO2013177534A3 (en) 2015-05-28
EP2854819A2 (en) 2015-04-08
JP6543366B2 (ja) 2019-07-10
US9650399B2 (en) 2017-05-16
US10377780B2 (en) 2019-08-13
JP2015522551A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
EP2854819B1 (en) Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and medical use thereof
ES2739814T3 (es) Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa
CN110423212B (zh) Shp2的基于羟基吲哚羧酸的抑制剂
KR101679400B1 (ko) 트라마돌 및 ＮＳＡＩＤｓ의 공결정
ES2539383T3 (es) Análogos arilesfingosina 1-fosfato bicíclicos
JP2013537535A (ja) Ｓｔａｔタンパク質の阻害剤としての、置換２−ヒドロキシ−４−（２−（フェニルスルホンアミド）アセトアミド）安息香酸類似体
CN103547152A (zh) 溴结构域蛋白的抑制剂作为基因表达的调节剂
WO2007136858A2 (en) Small molecule inhibitors of stat3 with anti-tumor activity
WO2014070859A1 (en) Stat3 dimerization inhibitors
CN108409663A (zh) 微管抑制剂及其制备方法和用途
EP3129354A1 (en) Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
US20220089531A1 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
CA2813571A1 (en) Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
US8895746B2 (en) Compounds that suppress cancer cells and exhibit antitumor activity
WO2018189679A1 (en) Isoindoline derivatives for use as ampk activators
WO2013178545A1 (en) Acid ceramidase inhibitors and their use as medicaments
WO2021143923A1 (zh) 硼酸衍生物
ES2348838T3 (es) Compuestos de cicloalquilideno como moduladores slectivos del receptor de estrã“genos.
HK40063807A (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180511

FZDE Discontinued

Effective date: 20210831